🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to our portfolio company Affinivax on their acquisition by GSK! A great move to advance their vaccines that combat novel and resistant infectious diseases that currently have no effective immunization strategies. wsj.com/articles/gsk-b…

Congratulations to Foresite Capital Fellow Xinhong Chen for his publication in Neuron on non-invasive gene delivery. We're so proud of his accomplishments! cell.com/neuron/fulltex…

Our managing director Michael Rome shares his thoughts on the Affinivax acquisition by GSK in our latest blog post: foresitecapital.com/blog/thoughts-…

This is a really impressive cohort, and we're so proud of our work with Venture Forward and our fellow supporting sponsors. It's small steps like these that will help bring about a more diverse and inclusive future for our industry.

Apply by June 24th for a full scholarship to #VCUniversity and the new life science track for aspiring life science investors from underrepresented backgrounds.

Cohort 11 looks solid! These individuals in the life sciences track will be shaping the future of our industry, and we couldn't be more proud to support this program with our friends at Venture Forward.

We're excited to be working with this precision oncology team to bring better, more targeted therapies to people with hard-to-treat cancers.

What do #PregnancyHealth experts say needs to change to reduce pregnancy-related death? Read Alison Cowan, M.D.’s perspective on the opportunities for prevention and the importance of patient education and empowerment in CNBC: cnbc.com/2022/10/03/cdc…

We're excited to support FOLX HEALTH as they scale their health and wellness platform designed uniquely for the LGBTQIA+ community. Thank you to Andrew Mendez and TechCrunch for this coverage.

Understanding who is at risk for pregnancy complications is the first step toward personalized preventive care. We are proud of the work being done to address this by our portfolio company Mirvie. Read Alison Cowan, M.D.’s interview with CNBC to learn more.

New podcast with the head of medical affairs at our portfolio company Mirvie on the state of maternal care and what is needed for meaningful change. The team at Mirvie has set out to identify risks months before symptoms occur.

Meet the Cohort 12 scholarship recipients!

Introducing our blog series featuring chats with our team members. Check out the conversation with Managing Director Michael Rome on the state of healthcare & his expert take on shaping trends & challenges. medium.com/foresite-capit…

Aspiring VCs from underrepresented backgrounds: Venture Forward is offering full scholarships to Cohort 13 (June 2023) of #VCUniversity, including course tuition, office hours, and dedicated mentorship. Learn more + apply by Friday, 3/24: venturecapitaluniversity.com/scholarship/on…

Proud to share the news that XinThera was acquired by Gilead Sciences today. We were the founding investor, seeing the potential in their approach to cancer and inflammatory diseases through drugs that block the proteins PARP1 or MK2. endpts.com/gilead-acquire…

Scholarship applications for Cohort 14 of #VCUniversity are now open! Created by Venture Forward, the scholarship covers tuition, office hours and a curated mentorship component that we’re proud to be a part of. Apply for the life sciences track by 6/23: bit.ly/3NjNXMY

Welcoming CG Oncology, Inc. to our portfolio! We're excited to work with Arthur Kuan and team to address the significant unmet need in bladder cancer. They are laser focused on delivering new treatment options for this difficult to treat patient population. Read more in FierceBiotech.

We welcome Hadi Tabbaa, our new managing director of investor relations and business development! With 2+ decades of experience, Hadi is set to strengthen our investor partnerships and bring invaluable expertise to Foresite Capital. Welcome aboard, Hadi! businesswire.com/news/home/2023…

Today we welcome @xaira_therapeutics to our portfolio, emerging from stealth with $1B in committed capital; jointly incubated by Arch Venture Partners / Robert Nelsen and Foresite Labs and led by Marc Tessier-Lavigne. Read more: endpts.com/in-biggest-eve…

Today we announced Fund VI, which represents hard work from many members of our team. So grateful to our investors for their support. Read more in FierceBiotech: @https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments